Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mochida Pharma President Announces Niche Expansion And Aims For ¥3 Billion Annul Revenue From Generic Drugs

This article was originally published in PharmAsia News

Executive Summary

Segmentation in the pharmaceutical industry creates many areas for mid-sized drug makers to explore, Mochida Pharma President Naoyuki Mochida stated at a press briefing. As a mid-sized enterprise, Mochida's niche in speed and specialization will allow it to compete with industrial giants, Mochida said. In 2008, Mochida Pharma will focus resources on four areas: cardiovascular drugs, obstetrics and gynecology, dermatological treatment and emergency medicines. Establishing strategic alliances with other pharmaceutical companies also creates opportunities to expand. Last February, Mochida Pharma signed a contract with Norvatis to jointly promote the anti-hypertension drug Diovan (valsartan). Regarding the company's generic drug business, Mr. Mochida expects to have a wider selection in products and has a goal of ¥3 billion in annual revenue. (Click here for more-Japanese language

You may also be interested in...

What’s Next? Five Things To Look Out For In December

Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.

European Commission Evaluating CBD Court Ruling Ahead Of Crucial UN Vote

With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.

UK First To Authorize Pfizer/BioNTech COVID-19 Vaccine

The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts